Want to see GB:SBTX full AI Analyst Report?
SkinBioTherapeutics (SBTX) Stock Statistics & Valuation Metrics
Total Valuation
SkinBioTherapeutics has a market cap or net worth of GBX 13.61M. The enterprise value is GBX 28.27T.
- Market Cap
- GBX 13.61M
- Enterprise Value
- GBX 28.27T
Share Statistics
SkinBioTherapeutics has 259,168,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 259,168,670
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
SkinBioTherapeutics’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -7.48%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.06
- Return on Invested Capital (ROIC)
- -7.48%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 113.13K
- Profits Per Employee
- -16.98K
- Employee Count
- 41
- Asset Turnover
- 0.38
- Inventory Turnover
- 2.42
Valuation Ratios
The current PE Ratio of SkinBioTherapeutics is -29.17. SkinBioTherapeutics’s PEG ratio is -0.19.
- PE Ratio
- -29.17
- PS Ratio
- 2.60
- PB Ratio
- 1.70
- Price to FCF
- -6.64
- Price to Operating Cash Flow
- -6.71
- PEG Ratio
- -0.19
Income Statement
In the last 12 months, SkinBioTherapeutics had revenue of 4.64M and earned -696.25K in profits. Earnings per share was 0.00.
- Revenue
- 4.64M
- Gross Profit
- 2.71M
- Operating Income
- -826.79K
- Pretax Income
- -715.12K
- Net Income
- -696.25K
- EBITDA
- -196.54K
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was -2.02M and capital expenditures -25,240, giving a free cash flow of -2.05M billion.
- Operating Cash Flow
- -2.02M
- Free Cash Flow
- -2.05M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
SkinBioTherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.07%
- Earnings Yield
- -3.36%
Stock Price Statistics
- Beta
- 0.05
- 52-Week Price Change
- -67.44%
- 50-Day Moving Average
- 7.31
- 200-Day Moving Average
- 9.98
- Relative Strength Index (RSI)
- 25.56
- Average Volume (3m)
- 2.02M
Important Dates
SkinBioTherapeutics upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jun 08, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
SkinBioTherapeutics as a current ratio of 4.84, with Debt / Equity ratio of 10.55%
- Current Ratio
- 4.84
- Quick Ratio
- 4.29
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 19.26
- Interest Coverage Ratio
- -8.99
Taxes
In the past 12 months, SkinBioTherapeutics has paid -18.86K in taxes.
- Income Tax
- -18.86K
- Effective Tax Rate
- 0.03
Enterprise Valuation
SkinBioTherapeutics EV to EBITDA ratio is -115.04, with an EV/FCF ratio of -5.57.
- EV to Sales
- 2.18
- EV to EBITDA
- -115.04
- EV to Free Cash Flow
- -5.57
- EV to Operating Cash Flow
- -5.64
Balance Sheet
SkinBioTherapeutics has GBX 3.12M in cash and marketable securities with GBX 939.16K in debt, giving a net cash position of GBX 2.19M billion.
- Cash & Marketable Securities
- GBX 3.12M
- Total Debt
- GBX 939.16K
- Net Cash
- GBX 2.19M
- Net Cash Per Share
- GBX 0.01
- Tangible Book Value Per Share
- GBX 0.01
Margins
Gross margin is 56.51%, with operating margin of -20.95%, and net profit margin of -8.73%.
- Gross Margin
- 56.51%
- Operating Margin
- -20.95%
- Pretax Margin
- -8.95%
- Net Profit Margin
- -8.73%
- EBITDA Margin
- -1.90%
- EBIT Margin
- -11.39%
Analyst Forecast
The average price target for SkinBioTherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 95.16%
- EPS Growth Forecast
- 85.60%
Scores
- Smart Score
- ―
- AI Score
- 51